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A B S T R A C T
Purpose
Colorectal cancer (CRC) develops as a result of a series of accumulated genomic changes that
produce oncogene activation and tumor suppressor gene loss. These characteristics may classify
CRC into subsets of distinct clinical behaviors.
Patients and Methods
We studied two of these genomic defects—mismatch repair deficiency (MMR-D) and loss of
heterozygosity at chromosomal location 18q (18qLOH)—in patients enrolled onto two phase III
cooperative group trials for treatment of potentially curable colon cancer. These trials included
prospective secondary analyses to determine the relationship between these markers and
treatment outcome. A total of 1,852 patients were tested for MMR status and 955 (excluding
patients with MMR-D tumors) for 18qLOH.
Results
Compared with stage III, more stage II tumors were MMR-D (21.3% v 14.4%; P  .001) and
were intact at 18q (24.2% v 15.1%; P  .001). For the combined cohort, patients with MMR-D tumors
had better 5-year disease-free survival (DFS; 0.76 v 0.67; P  .001) and overall survival (OS; 0.81 v 0.78;
P  .029) than those with MMR intact (MMR-I) tumors. Among patients with MMR-I tumors, the
status of 18q did not affect outcome, with 5-year values for patients with 18q intact versus 18qLOH
tumors of 0.74 versus 0.65 (P  .18) for DFS and 0.81 versus 0.77 (P  .18) for OS.
Conclusion
We conclude that MMR-D tumor status, but not the presence of 18qLOH, has prognostic value for
stages II and III colon cancer.
J Clin Oncol 29:3153-3162. © 2011 by American Society of Clinical Oncology
INTRODUCTION
In potentially curable colorectal cancer (CRC), cur-
rent staging methods do not optimally distinguish
between patients cured by surgery alone and those at
high risk of disease recurrence after surgery. When
classified using current clinicopathologic staging,
roughly 20% of patients with stage II colon cancer
will develop postsurgical disease recurrence, and it is
not possible to identify a high-risk subset of patients
with stage II disease who might benefit from adju-
vant chemotherapy. For patients with stage III CRC,
adjuvant chemotherapy has an established role; how-
ever,asignificantpercentageofpatientsreceivechem-
otherapy without benefit. These patients include
approximately one third of stage III patients whose
disease is cured after surgery alone and another 25%
whose disease recurs despite adjuvant treatment. It is
clearfromtheseobservationsthatbothpatientcareand
health care resource utilization would be dramati-
cally improved by developing tumor-specific mark-
ers that identify high- and low-risk CRC subsets.
CRCs accumulate specific genetic changes as
they develop from benign lesions to invasive tumors,
and the nature of these changes can divide CRCs
into distinct subsets.1 This study reports a prospec-
tive analysis of two genetic defects as predictors of
outcome for patients with stages II and III colon
cancer. The first marker involves an acquired defect
that produces an inability to repair single-nucleotide
DNA mismatches, a condition known as mismatch
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repair deficiency (MMR-D). Sporadic CRCs commonly acquire
MMR-D by methylation-associated silencing of MLH-1, a gene
encoding a key mismatch repair protein. Tumors with MMR-D
can be identified by frequent alterations in di- and trinucleotide
repeat sequences known as microsatellites, a condition termed
microsatellite instability high (MSI-H). A substantial body of data
indicates that patients with CRC whose tumors demonstrate
MMR-D (or MSI-H) have less aggressive disease. Studies from
randomized clinical trials have associated MMR-D status with
better prognosis after treatment of stages II and III disease and
suggested that these patients do not benefit from treatment with
fluorouracil (FU) -based adjuvant chemotherapy.2-8
Chromosomal instability (CIN), a condition of faulty segrega-
tion of sister chromatids during mitosis, is another genomic alteration
commonly observed in CRC. As a result of CIN, CRCs exhibit losses at
multiple tumor suppressor loci, particularly those located on 5q, 8p,
17p, and 18q. This process is distinct from MMR-D (ie, CRCs that
demonstrate CIN do not have MMR-D, and vice versa). Early studies
showed that patients whose tumors lacked regions on 18q as a result of
CIN experienced poor overall survival (OS) when compared with
patients whose tumors maintained intact 18q alleles.4,9 The most
common method used to detect 18q loss relies on assays that examine
two distinct alleles at a particular chromosomal location, a condition
known as heterozygosity. A normal tissue specimen is compared with
a tumor sample from the same patient, and DNA loss is identified if
one of the alleles present in the normal specimen is lost in the tumor, a
condition termed loss of heterozygosity (LOH). Although multiple
studies have examined the relationship between 18qLOH and treat-
ment outcome in patients with CRC, it is difficult to draw definitive
conclusions from the current literature because of conflicting data and
lack of comparability between studies.
Cancer and Leukemia Group B (CALGB) conducted separate
randomized trials of adjuvant therapy in patients with stages II
(CALGB protocol 9581) and III (CALGB protocol 89803) CRCs. Each
of these trials also included prospective determination of the relation-
ship between tumor MMR and 18q status and treatment outcome as
secondary study end points.
PATIENTS AND METHODS
Study Population
After tumor resection, patients with stage II CRC (n  1,738) were
randomly assigned to either receive edrecolomab or undergo observation
(CALGB 9581), and patients with stage III CRC (n  1,264) were randomly
assigned to receive either FU plus leucovorin (FU/LV) or FU, leucovorin, and
irinotecan (IFL; CALGB 89803; Figs 1, 2).10 The primary end point for both
trials was OS; disease-free survival (DFS) was a secondary end point. Second-
ary aims addressed the relationship between tumor-associated risk factors and
treatment outcome. These protocols were reviewed by the institutional review
board of each center; all patients provided written informed consent.
The CALGB Statistical Center (Durham, NC) maintained the research
database. Eligible patients were assigned by randomized fixed block to either
undergo observation or receive edrecolomab (CALGB 9581) or IFL or FU/LV
(CALGB 89803). Treatment description and results of CALGB 9581 are pro-
vided in Journal of Clinical Oncology by Niedzwiecki et al11; they have been
published previously for CALGB 89803.10
Detection of MSI and MMR-D
For each patient case, formalin-fixed paraffin-embedded primary tumor
and normal colon underwent histology confirmation by central pathology
review. Laboratory analysis was performed at Brigham and Women’s Hospital
(Boston, MA). Immunohistochemistry (IHC) detected the presence of mutL
homolog 1 (MLH1) and mutS homolog 2 (MSH2) proteins in primary tumor
specimens. Patient cases were scored as positive (defined as  10% of tumor
cells staining) or negative ( 10% tumor cells staining); MMR-D tumors had
a negative IHC score for either MLH1 or MSH2, whereas MMR intact
(MMR-I) tumors retained expression of both proteins.
DNA extracted from tumor was polymerase chain reaction amplified
using the following microsatellite markers: BAT25, BAT26, D17S250,
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Fig 1. CONSORT diagram, Cancer and
Leukemia Group B 9581.
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D5S346, ACTC, D18S55, BAT40, D10S197, BAT34c4, and MycL. Normal
control tissue was obtained from a separate nontumor tissue block; other-
wise, non-neoplastic control tissue was obtained by microdissection. Mi-
crodissection was performed when necessary to ensure greater than 60%
tumor within the sample. Tumors were designated MSI-H if instability was
identified at more than 50% of the loci screened, MSI low (MSI-L) if at least
one but fewer than 50% of the loci showed instability, and microsatellite
stable (MSS) if all loci were stable. For analysis, MSI-L and MSS patient
cases were combined and designated as MMR-I. Genotyping and IHC
results showed substantial agreement for both cohorts tested. Tumors
classified as MMR-D either lacked expression of MLH1 or MSH2 by IHC
or were MSI-H by genotyping.
18qLOH Determination
Tumor DNA was polymerase chain reaction amplified using the follow-
ing 18q markers: D18S69, D18S64, D18S61, D18S58, and D18S55. 18qLOH
was only scored in the absence of MSI-H (MMR-D by IHC or genotyping) and
was defined as peak ratio of tumor to normal greater than 1.35 or less than 0.67
for any individual marker. Markers with monoallelic results or microsatellite
instability were determined to be noninformative. Tumors were classified as
having 18qLOH if two or more markers were informative and demonstrated
this feature. Tumors were classified as 18q intact if two or more markers were
informative and did not indicate LOH.
Statistical Methods
The primary study end point was OS measured from trial entry until
death as a result of any cause. DFS was measured from study entry until
documented disease progression or death as a result of any cause. Secondary
goals determined whether tumor MMR or 18qLOH status identified better
response to a particular study treatment. Relationships between tumor marker
status and clinical pathologic factors were studied using Pearson 2 and Sat-
terthwaite t tests; continuous factors with more than two groups were tested
using Wilcoxon rank sum test. In the combined data set, moderate to large
DFS hazard ratios (HRs;1.7) were detectable for MMR with adequate power
( 0.7) with the numbers of DFS events observed (two-sided   0.025); only
large DFS HRs ( 1.90) were detectable for 18qLOH. Differences detectable
with adequate power for OS and within trial and treatment subgroups were
even greater ( 2.0).
A Cox model tested interactions between study and marker status and
treatment arm and marker status, and log-rank test compared survival
among categories defined by marker status and study or treatment and
within study, marker, and treatment subgroups. The proportional hazards
model was used compare survival controlling for study, treatment, and
other clinicopathologic factors. Graphical techniques and Schoenfeld re-
siduals assessed the validity of model assumptions and model fit. The
Kaplan-Meier method estimated the DFS and OS curves and 3- and 5-year
survival probabilities. Pointwise CIs for the product limit estimate of the
survival function were based on Greenwood’s formula. All outcome anal-
yses were conducted in the subset of patients in which MMR status was
available by either IHC or genotyping, and data were analyzed with con-
tinued follow-up for DFS and OS as of December 4, 2009 (CALGB 9581),
and November 9, 2009 (CALGB 89803).
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RESULTS
Characteristics of the Study Population
At least one marker was tested in specimens from 939 (54%)
of the 1,738 patients randomly assigned in CALGB 9581 and 913
(72%) of the 1,264 patients enrolled onto CALGB 89803 (Figs 3A
to 3C). For both studies combined, a total of 1,852 (62%) patients
were tested for MMR status and 955 (32%; excludes those with
MMR-D tumors) for 18qLOH. There was no imbalance in treat-
ment assignment for either trial overall or for the MMR and
18qLOH analysis subsets (Table 1; Appendix Table A1, online
only). Of tumors tested, technical issues (eg, insufficient tissue
quality, allelic dropout) led to a 0.4% noninformative rate for
MMR and 14.5% noninformative rate for 18qLOH testing.
Relationships Between Marker Status and
Clinicopathologic Factors
Tumors with MMR-D were more proximally located and more
poorly differentiated in both the stage II and III cohorts (Table 2).
Stage III MMR-D tumors were more common in women than in men
(55% v 45%; P .020) and had a lower mean nodes ratio than MMR-I
tumors (0.25 v 0.31; P  .005). Stage II cancers with 18qLOH were
more likely to be in a distal location (51.4% v 38%; P  .046).
Stage-Associated Differences in Marker Prevalence
Comparison of the two study cohorts revealed stage-associated
differences in marker prevalence (Appendix Table A2, online only). As
expected from previous studies, more stage II tumors were MMR-D
(21.3% v 14.4%; P .001). Patient cases tested for 18qLOH were those
that did not demonstrate MMR-D. Among these, fewer stage III
tumors were intact at 18q (15.1% v 24.2%; P  .001). These relation-
ships remained the same with and without correction for noninfor-
mative patient cases.
Prognostic Marker Evaluation
No significant interactions for DFS or OS were detected by test-
ing for interaction between marker status and study for MMR and
18qLOH results. The relationships between marker status and out-
come were then examined for the stage II and III study cohorts com-
bined. Patients with MMR-D tumors experienced better 5-year DFS
(0.76 v 0.67; HR, 0.69; log-rank P  .001) and 5-year OS (0.81 v 0.78;
HR, 0.77; log-rank P  .029) than those with MMR-I tumors (Table 3;
Figs 4A, 4B). Tumor 18qLOH status was not associated with a differ-
ence in outcome when patients of both stages were considered to-
gether (Figs 4C, 4D).
The prognostic significance of the markers was examined for
each trial independently. Among patients with stage II disease
(CALGB 9581), those with MMR-D tumors experienced significantly
better DFS than those with MMR-I tumors (Table 3; 0.84 v 0.75; HR,
0.65; P  .008). This association was similar for OS; however, statisti-
cal significance was not reached (0.86 v 0.84; P  .12). The presence of
tumor 18qLOH was not prognostic for patients with stage II disease.
In patients with stage III disease (CALGB 89803), neither tumor MMR
status nor 18qLOH was associated with a significant difference in
treatment outcome.
Most studies of the relationship between tumor 18q status and
clinical behavior have excluded MMR-D patient cases from compar-
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Fig 3. Association between marker status and treatment outcome. Results of analysis
examining association between mismatch repair (MMR) and 18q status and protocol
treatment outcome (disease-free survival [DFS] and overall survival [OS] denote Kaplan-
Meier estimates at 5 years; P values are associated with the log-rank test). Cohorts
included (A) stage II patients treated on Cancer and Leukemia Group B (CALGB) 9581,
(B) stage III patients treated on CALGB 89803, and (C) stage II and III patients treated on
either CALGB 9581 or 89803. 18qLOH, loss of heterozygosity at chromosomal location
18q; MMR-D, mismatch repair deficiency; MMR-I, mismatch repair intact.
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isons between 18qLOH and 18q intact patient cases.12-22 However, in
a few often-cited reports, MSI-H patient cases were analyzed together
with others that showed no 18qLOH.4,9,23 To compare our results
with those from these earlier studies, we combined the MMR-D and
the 18q intact patient cases and studied differences in outcome be-
tween these patients and those whose tumors had 18qLOH (Figs 4E,
4F). This analysis showed significantly worse 5-year DFS and OS for
patients whose tumors demonstrated 18qLOH. In the combined co-
hort of stage II and III patients, 5-year DFS was 0.65 (95% CI, 0.61 to
0.69) versus 0.75 (95% CI, 0.71 to 0.79; log-rank P .021), and OS was
Table 1. Demographics and Clinical Characteristics of the Study Cohort
Characteristic





PNo. % No. % No. % No. %
No. of patients 939 799 353 1,385
Treatment .35 .039
MoAb 17-1A 477 50.8 388 48.6 193 54.7 672 48.5
Observation 462 49.2 411 51.4 160 45.3 713 51.5
Age, years .09 .74
Mean 65 64 64 64
Range 30-90 24-88 33-89 24-90
Sex .62 .23
Female 447 47.6 390 48.8 160 45.3 677 48.9
Male 492 52.4 409 51.2 193 54.7 708 51.1
Tumor location .87  .001
Distal 367 39.2 304 38.8 169 48.0 502 36.7
Proximal 569 60.1 479 61.2 183 52.0 865 63.3
Tumor differentiation .98 .049
Well 80 8.6 66 8.4 33 9.4 113 8.3
Moderate 709 70.0 596 75.8 278 79.2 1,027 75.0
Poor/undifferentiated 144 15.4 124 15.8 40 11.4 228 16.7
Mean No. of nodes sampled 14.0 14.8 .12 13.6 14.6 .07
Stage III Patients: CALGB 89803
MMR-D 18qLOH
Analyzed Not Analyzed Analyzed Not Analyzed
No. % No. % P No. % No. % P
No. of patients 913 351 602 662
Treatment .65 .78
FU/LV 458 50.2 171 48.7 302 50.2 327 49.4
IFL 455 49.8 180 51.3 300 49.8 335 50.6
Age, years .97 .91
Mean 60 60 60 60
Range 21-85 26-82 24-85 21-85
Sex .25 .33
Female 415 45.5 147 41.9 2,590 43.0 303 45.8
Male 498 54.5 204 58.1 343 57.0 359 54.2
Tumor location .84  .001
Distal 382 42.4 139 41.7 286 48.0 235 36.8
Proximal 519 57.6 194 58.3 310 52.0 403 63.2
Tumor differentiation .93  .001
Well 50 5.5 20 6.0 32 5.4 38 6.0
Moderate 629 69.7 232 69.9 451 75.5 410 64.3
Poor/undifferentiated 224 24.8 80 24.1 114 19.1 190 29.8
Positive nodes .66 .48
Mean 3.6 3.5 3.6 3.6
Range 1-29 0-22 1-24 0-29
Nodal ratio .44 .43
Mean 0.30 0.31 0.31 0.30
Range 0-1 0-1 0-1 0-1
Nodes sampled .14 .019
Mean 14.6 13.8 13.8 15
Range 1-99 1-68 1-99 1-68
Abbreviations: 18qLOH, loss of heterozygosity at chromosomal location 18q; CALGB, Cancer and Leukemia Group B; FU/LV, fluorouracil plus leucovorin; IFL,
fluorouracil, leucovorin, and irinotecan; MMR-D, mismatch repair deficiency; MoAb 17-1A, monoclonal antibody 17-1A.
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Table 2. Marker Prevalence and Association With Histopathologic Variables
Characteristic
Stage II Patients: CALGB 9581















PNo. % No. % No. % No. % No. %
No. of patients 199 736 71 222 60
Treatment .76 .54
MoAb 17-1A 103 51.8 372 50.5 43 60.6 118 53.2 32 53.3
Observation 96 48.2 364 49.5 28 39.4 104 46.8 28 46.7
Age, years .24 .66
Mean 65 64 63 65 64
Range 30-87 33-90 36-87 33-89 38-79
Sex .002 .37
Male 85 42.7 405 55.0 35 49.3 121 54.5 37 61.7
Female 114 57.3 331 45.0 36 50.7 101 45.5 23 38.3
Site of tumor  .001 .13
Distal 27 13.6 339 46.6 27 38.0 114 51.4 28 46.7
Proximal 72 86.4 394 53.5 44 62.0 107 48.2 32 53.3
Unknown 0 3 0.4 0 1 0.4
Tumor differentiation  .001 .40
Well 12 6.0 68 9.2 6 8.4 21 9.5 6 10.0
Moderate 122 61.3 584 79.4 53 74.6 175 78.8 50 83.3
Poor/undifferentiated 64 32.2 79 10.7 12 16.9 25 11.3 3 5.0
Unknown 1 0.5 5 0.7 0 1 0.4 1 1.7
Nodes sampled  .001 .24
Mean 16.6 13.4 14.4 13.8 11.8
Range 3-49 0-59 3-59 1-51 0-47
Stage III Patients: CALGB 89803














No. % No. % P No. % No. % No. % P
No. of patients 131 779 79 445 78
Treatment .47 .58
FU/LV 62 47.3 395 50.7 39 49.4 228 51.2 35 44.9
IFL 69 52.7 384 49.3 40 50.6 217 48.8 43 55.1
Age, years .52 .025
Mean 61 60 59 60 63
Range 21-85 24-85 35-80 24-85 39-85
Sex .020 .82
Male 59 45 436 56 45 57.0 251 56.4 47 57.0
Female 72 55 343 44 34 43.0 194 43.6 31 43.0
Site of tumor  .001 .69
Distal 14 10.7 366 47 39 49.37 208 46.7 39 50.0
Proximal 115 87.8 403 51.7 37 46.84 235 52.8 38 48.7
Unknown 2 1.5 10 1.3 3 3.8 2 0.4 1 1.3
Tumor differentiation  .001 .20
Well 2 1.5 48 6.2 0 26 5.8 6 7.8
Moderate 63 48.1 564 72.4 63 79.8 332 74.6 56 72.7
Poor/undifferentiated 64 48.9 159 20.4 13 16.5 86 19.3 15 19.5
Unknown 2 1.5 8 1 3 3.8 1 0.2 0
Positive nodes .95 .28
Mean 3 3 4 3.4 3.5
Range 1-23 1-29 1-16 1-24 1-23
Nodal ratio .005 .64
Mean 0.25 0.31 0.32 0.3 0.33
SD 0.21 0.25 0.26 0.24 0.27
Nodes sampled .007 .32
Mean 16.7 14.3 13.9 14.0 12.4
Range 2-68 1-99 4-45 1-99 1-27
Abbreviations: 18qLOH, loss of heterozygosity at chromosomal location 18q; CALGB, Cancer and Leukemia Group B; FU/LV, fluorouracil plus leucovorin; IFL,
fluorouracil, leucovorin, and irinotecan; MMR, mismatch repair; MMR-D, mismatch repair deficiency; MMR-I, mismatch repair intact; MoAb 17-1A, monoclonal
antibody 17-1A; SD, standard deviation.
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0.77 (95% CI, 0.73 to 0.80) versus 0.81 (95% CI, 0.77 to 0.84; log-rank
P  .002), for those with and without 18qLOH, respectively.
The following variables were considered simultaneously in a regres-
sion model with MMR: study, sex, age, performance status, race, tumor
location, tumor grade, number of nodes sampled, tumor invasion depth,
and extramural vascular invasion. Of these, study, sex, age at study entry,
performance status, tumor grade, number of nodes sampled, tumor in-
vasion depth, and extramural vascular invasion were significantly re-
lated to DFS and OS (Appendix Table A3, online only). MMR-D
remained significant for DFS (P  .012) and OS (P  .016) when
other prognostic variables were considered in the respective models.
Enrollment onto study CALGB 9581, female sex, having more nodes
examined, and tumor MMR-D decreased the risk of recurrence or
death. All other variables increased the risk of recurrence or death as
they increased in value.
Predictive Marker Evaluation
Neither CALGB 9581 nor CALGB 89803 demonstrated signifi-
cant differences in outcome between study treatment arms. When we
examined the relationship between study treatment and marker sta-
tus, neither MMR-D nor 18qLOH predicted better response to a
particular regimen (Table 4). An earlier report from CALGB 89803
examined the association between tumor MMR-D status and re-
sponse to adjuvant chemotherapy and found improved DFS in pa-
tients receiving IFL whose tumors were MMR-D.24 The analysis
presented here uses an available IHC result preferentially over an
available genotyping result, whereas the previous paper reported re-
sults in the subset of patients with agreement between IHC and geno-
typing. Consequently, the number of patients with MMR results was
increased from 702 in the previous study to 913 in the current study.
Using the updated data set for patients with agreement between IHC
and genotyping results, a significant interaction between MMR status
and treatment in stage III patients continued to be observed (interac-
tion HR, 0.41; P  .026).
DISCUSSION
This study confirms an association between tumor MMR status and
CRC clinical behavior, showing that tumors with MSI-H are less likely
to metastasize or recur after surgery. These data also indirectly support
those of other stage III colon cancer adjuvant trials, suggesting that
patients with MMR-D tumors do not benefit from FU-based treat-
ment.6,7 In our study, the association between favorable outcome and
MMR-D status was significant for DFS in the stage II cohort alone and
in the stages II and III combined analysis but not in the stage III cohort.
Because none of the stage II and all of the stage III patients received
adjuvant chemotherapy containing FU, it is possible that better out-
come for the MMR-D stage III subset was not observed because it was
negated by MMR-D–associated lack of response to FU. In addition,
for the stage II patients, DFS but not OS was better for patients whose
tumors were MMR-D. This would be explained if the patients with
MMR-D tumors whose disease recurred went on to receive, and not
benefit from, second-line chemotherapy containing FU.
The region of 18q lost during CRC development contains a
number of important tumor suppressor genes.25-27 Losses of 18q
alleles were first associated with CRC treatment outcome in a 1996
retrospective analysis of DCC protein expression by Shibata et al.28
Although a large number of subsequent studies have examined the
relationship between 18qLOH and CRC clinical outcome, the results
are difficult to interpret. Available reports are almost equally di-
vided between those finding that tumor 18qLOH predicted poor
survival4,9,14-16,23,26,29-32 and those showing no association between
tumor 18q status and treatment outcome.12,13,17,19-21,33-36 Most












P HR 95% CI
All-patient analysis 3,002 0.72 0.70 to 0.73 0.80 0.78 to 0.81
All patients with MMR-I tumors 1,515 0.67 0.64 to 0.69  .001 0.78 0.75 to 0.80 .029
All patients with MMR-D tumors 330 0.76 0.71 to 0.80 0.69 0.55 to 0.86 0.81 0.76 to 0.84 0.77 0.61 to 0.97
All patients with 18q intact tumors 150 0.74 0.66 to 0.80 .18 0.81 0.73 to 0.86 .18
All patients with 18qLOH tumors 667 0.65 0.61 to 0.69 1.2 0.91 to 1.68 0.77 0.73 to 0.80 1.26 0.89 to 1.79
All patients with noninformative 18qLOH 138 0.66 0.57 to 0.73 .39 1.01 0.97 to 1.05 0.72 0.63 to 0.79 .30 1.02 0.98 to 1.06
Stage II patients (CALGB 9581)
Stage II patients with MMR-I tumors 736 0.75 0.72 to 0.78 .008 0.84 0.81 to 0.86 .12
Stage II patients with MMR-D tumors 199 0.84 0.77 to 0.88 0.65 0.47 to 0.89 0.86 0.81 to 0.91 0.76 0.54 to 1.07
Stage II patients with 18q intact tumors 71 0.77 0.65 to 0.86 .90 0.82 0.70 to 0.89 .78
Stage II patients with 18qLOH tumors 222 0.79 0.73 to 0.84 1.03 0.62 to 1.73 0.87 0.82 to 0.91 0.92 0.53 to 1.61
All patients with noninformative 18qLOH 60 0.80 0.67 to 0.89 .79 0.98 0.91 to 1.05 0.85 0.73 to 0.92 .85 0.98 0.91 to 1.06
Stage III patients (CALGB 89803)
Stage III patients with MMR-I tumors 779 0.59 0.56 to 0.63 .20 0.72 0.68 to 0.75 .42
Stage III patients with MMR-D tumors 131 0.65 0.56 to 0.73 0.82 0.60 to 1.11 0.72 0.64 to 0.79 0.88 0.63 to 1.22
Stage III patients with 18q intact tumors 79 0.70 0.59 to 0.79 .32 0.80 0.69 to 0.87 .17
Stage III patients with 18qLOH tumors 445 0.58 0.54 to 0.63 1.22 0.83 to 1.78 0.72 0.67 to 0.76 1.38 0.87 to 2.17
All patients with noninformative 18qLOH 78 0.55 0.43 to 0.65 .24 1.03 0.99 to 1.08 0.62 0.50 to 0.72 .09 1.04 1.00 to 1.09
Abbreviations: 18qLOH, loss of heterozygosity at chromosomal location 18q; CALGB, Cancer and Leukemia Group B; DFS, disease-free survival; HR, hazard ratio;
MMR-D, mismatch repair deficiency; MMR-I, mismatch repair intact; OS, overall survival.
Statistics when tested as a third group with the 18qLOH tumors and 18qLOH intact tumors.
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studies involved retrospective analysis of archival specimens from
surgical cohorts, with only four studies reporting retrospective
analyses of tumors from patients participating in either a random-
ized treatment trial or prospective cohort study. Of these, one
found worse outcome for patients with 18qLOH-positive tumors,4
one reported better outcome for a subset of patients with 18qLOH-
positive tumors,18 and two found no association between 18q
status and outcome.17,19 Finally, two prospective clinical trials
studied the relationship between tumor 18q status and outcome as
secondary end points in a colon cancer treatment study.20,21 Nei-
ther of these studies found a significant association between tumor
18q status and outcome.
One reason for difficulty interpreting the data on the association
between tumor 18q loss and clinical response has been confusion intro-
duced by variable assignment of the MMR-D subset. Two early studies
showing an association between 18qLOH and poor treatment outcome
included patients with MMR-D tumors as well as those with 18q intact
tumors and compared this combined group with patients whose tumors
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2 4 6 8 10 12
  n Event Censored 
18q intact 150 33% (49) 67% (101)
18qLOH 667 38% (256) 62% (411)
Noninformative 138 37% (51) 63% (87)
  n Event Censored 
18q intact + MMR-D 480 25% (119) 75% (361)
18qLOH 667 31% (209) 69% (458)
  n Event Censored 
18q intact + MMR-D 480 29% (141) 71% (339)
18qLOH 667 38% (256) 62% (411)
Fig 4. Kaplan-Meier estimates for the combined data set of stage II (Cancer and Leukemia Group B [CALGB] 9581) and stage III (CALGB 89803) patients, repre-
senting comparisons between different marker-defined subsets. (A) Overall survival (OS; all-cause death) by mismatch repair (MMR) status (log-rank P  .029); (B)
disease-free survival (DFS; documented recurrence of primary colon cancer or death as a result of any cause) by MMR status (log-rank P  .001); (C) OS by 18q status
(log-rank P  .32); (D) DFS by 18q status (log-rank P  .39); (E) OS by 18q status with MMR deficiency (MMR-D) included among 18q intact (log-rank P  .021);
(F) DFS by 18q status with MMR-D included among 18q intact (log-rank P  .002). 18qLOH, loss of heterozygosity at chromosomal location 18q; MMR-I, mismatch
repair intact.
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demonstrated18qLOH.4,9 GiventhebetteroutcomeamongtheMMR-D
patientcases,the18qresultcouldhavebeenaffectedbyconfounding.This
issue was addressed by Halling et al,17 who found worse outcome in
patientswith18qLOHtumorswhencomparedwithacombinedgroupof
patients with 18q intact and MMR-D tumors. For this study, prognostic
significance of tumor 18qLOH was no longer present when the patients
with MMR-D tumors were excluded. The results of our study are in
agreement with those of Halling et al and show that independent of
MMR-D status, tumor 18qLOH determination does not have prognos-
tic significance.
In a previous analysis of CALGB 89803, we found that patients
with MMR-D tumors who received IFL experienced improved treat-
ment outcome, with 5-year DFS of 0.76 versus 0.59 (P  .03) and OS
of 0.78 versus 0.70 (P  .23). When a predictive analysis was con-
ducted within the MMR-D/MSI-H tumor subtype, this result failed to
achieve significance (DFS, P .07; OS, P .27; n96). In the current
analysis, MMR status was determined using an algorithm that selected
the IHC result when available and the genotyping result when no IHC
result was available. This increased the sample size by more than 200
patients to the 913 patients in the current study, and follow-up was
also updated to November 9, 2009. In this updated analysis, we con-
tinued to observe a marginally significant increase in DFS among
patients with MMR-D tumors treated with IFL versus patients with
MMR-I tumors treated with IFL (P  .055). The interaction HR for
MMR status by treatment using this definition was 0.612 (P  .12).
However, when MMR/MSI status was defined based on agreement
between IHC and genotyping results, as previously reported,we again
observed a significant interaction of MMR/MSI status by treatment
(interaction HR, 0.418; P  .026). Thus, the previous results were
strengthened with additional follow-up.
In conclusion, we found that patients with MMR-D stage II
colon cancers had improved outcome after surgical resection.
Analysis of tumor 18q status was of prognostic value for neither
stage II nor III patient cases. Finally, neither of these markers
predicted differential response to either adjuvant chemotherapy
with edrecolomab or IFL,and additional study is required to












P HR 95% CI
Stage II predictive analysis
Patients with MSI deficient tumors
Treated with MoAb 17-1A 103 0.86 0.77 to 0.91 .52 0.87 0.79 to 0.93 .52
Observation 96 0.82 0.72 to 0.88 1.21 0.68 to 2.18 0.86 0.77 to 0.91 1.22 0.66 to 2.26
Patients with MSI intact tumors
Treated with MoAb 17-1A 372 0.74 0.70 to 0.79 .75 0.85 0.81 to 0.88 .84
Observation 364 0.76 0.71 to 0.80 0.96 0.74 to 1.24 0.83 0.79 to 0.87 1.03 0.78 to 1.37
Patients with 18qLOH tumors
Treated with MoAb 17-1A 118 0.76 0.67 to 0.83 .06 0.88 0.80 to 0.92 .26
Observation 104 0.83 0.74 to 0.89 0.61 0.36 to 1.03 0.86 0.78 to 0.92 0.72 0.40 to 1.28
Patients with 18q intact tumors
Treated with MoAb 17-1A 43 0.74 0.57 to 0.85 .99 0.82 0.66 to 0.91 .60
Observation 28 0.82 0.61 to 0.89 1.00 0.40 to 2.50 0.81 0.61 to 0.92 1.29 0.50 to 3.34
Patients with noninformative tumors
Treated with MoAb 17-1A 32 0.80 0.61 to 0.91 .91 0.83 0.64 to 0.95 .81
Observation 28 0.80 0.58 to 0.91 0.94 0.32 to 2.80 0.88 0.67 to 0.96 0.86 0.26 to 2.84
Stage III predictive analysis
Patients with MMR-D tumors
Treated with FU/LV 62 0.60 0.46 to 0.71 .18 0.71 0.57 to 0.81 .62
Treated with IFL 69 0.69 0.57 to 0.79 0.68 0.38 to 1.20 0.74 0.61 to 0.82 0.85 0.46 to 1.59
Patients with MMR-I tumors
Treated with FU/LV 395 0.61 0.56 to 0.65 .44 0.73 0.68 to 0.77 .78
Treated with IFL 384 0.58 0.52 to 0.62 1.09 0.88 to 1.34 0.70 0.65 to 0.74 1.03 0.82 to 1.31
Patients with 18qLOH tumors
Treated with FU/LV 228 0.58 0.51 to 0.64 .49 0.72 0.66 to 0.78 .39
Treated with IFL 217 0.59 0.52 to 0.65 0.90 0.68 to 1.20 0.71 0.65 to 0.77 0.87 0.64 to 1.19
Patients with 18q intact tumors
Treated with FU/LV 39 0.72 0.55 to 0.83 .63 0.79 0.62 to 0.89 .54
Treated with IFL 40 0.69 0.52 to 0.81 1.20 0.58 to 2.45 0.81 0.64 to 0.90 0.76 0.32 to 1.81
Patients with noninformative tumors
Treated with MoAb 17-1A 35 0.60 0.42 to 0.74 .51 0.69 0.50 to 0.81 .57
Observation 43 0.51 0.35 to 0.65 1.24 0.65 to 2.37 0.57 0.40 to 0.70 1.22 0.61 to 2.44
Abbreviations: 18qLOH, loss of heterozygosity at chromosomal location 18q; DFS, disease-free survival; FU/LV, fluorouracil plus leucovorin; HR, hazard ratio; IFL,
fluorouracil, leucovorin, and irinotecan; MMR-D, mismatch repair deficiency; MMR-I, mismatch repair intact; MoAb 17-1A, monoclonal antibody 17-1A; MSI,
microsatellite instability; OS, overall survival.
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understand the benefit of FU-based adjuvant chemotherapy in
patients with MMR-D colon cancer.
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